Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Sun Yat-sen University

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine

Study type: Observational

Funder types: Other

Identifiers

NCT06373744

SYSU-022

Details and patient eligibility

About

The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is:

How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.

Enrollment: 597 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Females, >18 years old;
2. Diagnosed with advanced breast cancer when using metronomic chemotherapy;
3. At least one clinical evaluation, including physical examination and imaging, according to the instructions of the supervising physician during the use of metronomic chemotherapy. Examinations include ultrasound, computed tomography, and magnetic resonance imaging;
4. Metronomic chemotherapy can be used alone, and patients who use it in combination with other drugs can also be included;
5. The clinical pathological information that needs to be collected is complete.

Exclusion criteria

1. Taking the drug for less than 2 weeks;
2. losing follow-up after taking the therapy;
3. The patient's breast cancer was still in the early stage when taking the therapy.

Trial design

597 participants in 1 patient group

metronomic chemotherapy

Description:

Patients with advanced breast cancer who received metronomic chemotherapy.

Treatment:

Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine